Tri Locum Partners’s Passage Bio PASG Stock Holding History

Tri Locum Partners’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,133	Closed	-$31K	–	76
2022 Q4	$31K	Buy	+1,133	New	+$28.6K	0.01%	62

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Tri Locum Partners's PASG Position: Q1 2023 in Review

Tri Locum Partners sold out of Passage Bio (PASG) in Q1 2023, closing a stake of 1,133 shares — an estimated $31K sold.

Tri Locum Partners first reported a position in PASG in Q4 2022 and held it in 1 quarter. The position peaked at $31K in Q4 2022. 58 funds tracked by Wall St. Rank hold PASG as of Q1 2023.

Tri Locum Partners reported no remaining Passage Bio position as of Q1 2023 after selling out during the quarter.
Tri Locum Partners sold 1,133 Passage Bio shares in Q1 2023, an estimated $31K.
Tri Locum Partners first reported a position in Passage Bio in Q4 2022 and held it in 1 quarter.
Tri Locum Partners's Passage Bio position peaked at $31K in Q4 2022.
58 funds tracked by Wall St. Rank held Passage Bio as of Q1 2023.

Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.